Aptahem ABXSAT:APTA -1.14%30 Market Cap is kr13.49 Mil as of Jun. 30, 2026. GuruFocus rates XSAT:APTA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,428 Biotechnology companies, Aptahem AB ranks worse than 96.85% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aptahem AB's share price for the quarter that ended in Mar. 2026 was kr0.631428. Aptahem AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 21.59 Mil. Therefore, Aptahem AB's market cap for the quarter that ended in Mar. 2026 was kr13.63 Mil.
Aptahem AB's quarterly market cap
increased
from Sep. 2025 (kr23.22 Mil) to Dec. 2025 (kr24.01 Mil) but then
declined
from Dec. 2025 (kr24.01 Mil) to Mar. 2026 (kr13.63 Mil).
Aptahem AB's annual market cap
declined
from Dec. 2023 (kr18.63 Mil) to Dec. 2024 (kr17.75 Mil) but then
increased
from Dec. 2024 (kr17.75 Mil) to Dec. 2025 (kr24.01 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aptahem AB's Enterprise Value for Today is kr9.35 Mil.
Aptahem AB (XSAT:APTA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aptahem AB Market Cap Related Terms
Aptahem AB Market Cap Historical Data
* Premium members only.
The historical data trend for Aptahem AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:APTA vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Aptahem AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptahem AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptahem AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Aptahem AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aptahem AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptahem AB (XSAT:APTA) has a Market Cap of kr13.49 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aptahem AB and its competitors. According to the industry distribution chart, Aptahem AB ranks #1383 out of 1428 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Aptahem AB's Market Cap too high?
Aptahem AB's current Market Cap is kr13.49 Mil. Based on the distribution chart, Aptahem AB ranks #1383 out of 1428 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptahem AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aptahem AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptahem AB ranks #1383 out of 1428 companies for Market Cap. This places Aptahem AB in the lower half of its industry. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aptahem AB and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptahem AB's current Market Cap is kr13.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptahem AB stock overvalued right now?
Aptahem AB (XSAT:APTA) has a current Market Cap of kr13.49 Mil. The current Market Cap is kr13.49 Mil. Aptahem AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aptahem AB (XSAT:APTA), the current Market Cap is kr13.49 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.
30GF Score
Get the complete analysis for XSAT:APTA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:APTA has been successfully added to your 
